基于外泌体递送WTAP siRNA改善心肌缺血再灌注损伤
核心信息
- 论文英文标题: Exosome-based WTAP siRNA delivery ameliorates myocardial ischemia-reperfusion injury
- 期刊: Eur J Pharm Biopharm
- 发表年份: 2024
- DOI: 10.1016/j.ejpb.2024.114218
- PMID/PMCID: 38367759
研究概览
In the present study, we observed the up-regulation of the m6A mRNA methylation complex component Wilms' tumor 1-associating protein (WTAP) in MI/R mice, which led to the m6A modification of TXNIP mRNA and an increase in mRNA abundance. The increased expression of Thioredoxin-interacting protein (TXNIP) has been implicated in MI/R injury, although the detailed mechanism remains incompletely understood.
核心发现
Myocardial ischemia/reperfusion (MI/R) injury is the primary cause of postischemicheartfailure.
The increased expression of Thioredoxin-interacting protein (TXNIP) has been implicated in MI/R injury, although the detailed mechanism remains incompletely understood.
In the present study, we observed the up-regulation of the m6A mRNA methylation complex component Wilms' tumor 1-associating protein (WTAP) in MI/R mice, which led to the m6A modification of TXNIP mRNA and an increase in mRNA abundance.
Knock-down of WTAP resulted in a significant reduction in the m6A level of TXNIP mRNA and down-regulated TXNIP expression.
Echo Biotech 角色
ContrExo 293F外泌体参考品&IMTP脂锚
关联平台: Echosome®, EV Materials / Reference Materials, Research Reagents & Tools
关联服务与能力: Targeting Peptide / Surface Modification, EV Material / Reference Material Supply
关联产品或试剂: ExoBrooch™ Targeting Peptide/Lipid Anchor Kit, ContrExo® EV Reference Material
参考文献
原始论文: Exosome-based WTAP siRNA delivery ameliorates myocardial ischemia-reperfusion injury Eur J Pharm Biopharm. 2024. DOI: 10.1016/j.ejpb.2024.114218. PMID/PMCID: 38367759.